Date: Wed 12/05/2021 - Fri 12/05/2023
Optometrist Credits: 0.75 General credits
Event Type(s): Article, Online
Number: 09 929 3273
The introduction of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy two decades ago, heralded a paradigm shift in the treatment of neovascular age-related macular degeneration (nAMD). Clinical trials have consistently shown a mean functional improvement of +6.5 to +10.5 letter visual gain, with six to 13 injections required over 12 months, depending on the treatment regimen followed.1–3 Similarly, there is a reduction in central retinal thickness (CRT) and decreased exudation of fluid on opticalcoherence tomography (OCT) scans following anti-VEGF therapy.